Recapitulating the Orthotopic Tumor Microenvironment using Bioluminescent Syngeneic Models in Immune Competent Mice for Checkpoint Inhibitor Interrogation
Joyce Obeng, Maya Jetha, Jane Wrigley, Simon Jiang, Jason King, Bryan Miller, Rajendra Kumari, Yinfei Yin
Orthotopic syngeneic models provide a more clinically relevant tumor microenvironment for immuno-oncology drug development studies. This includes an organ-specific tumor location, which allows metastasis, and also recapitulates immune and stromal component tumor interactions.
Bioluminescent imaging (BLI) enables real-time, non-invasive longitudinal monitoring of orthotopic tumor burden and end stage quantification of tumor spread.
This poster details the generation of a panel of bioluminescent syngeneic cell lines for orthotopic and metastatic modeling. These models allow the assessment of standard of care agents, immune checkpoint therapies, and combination regimens in a more clinically relevant environment.
Read this Poster to Discover:
- How the orthotopic microenvironment, with appropriate organ-specific vasculature, hypoxia, and stromal infiltration, provides the ideal model to assess immunotherapies, the response of which is heavily dependent on the TME
- How BLI enables longitudinal assessment of orthotopic tumors, which provides real-time quantification of tumor progression and therapeutic effect, with TIL assessed by IHC or FACS
- How bioluminescent imaging also allows the tracking of spontaneous metastasis and experimental metastasis models.